# General Technology Venture Capital

> General Technology Venture Capital is a VC fund backing Biotechnology. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 9
- Last investment: Jul 2023
- Lead investor: 33%
- Last updated: Aug 2026
- Website: http://www.gtimvc.com.cn/

General Technology Venture Capital is an investment firm focused on domestic and overseas investments and M&A projects.

## Contacts

5 contacts available for General Technology Venture Capital. Shizune tracks 1 team members at General Technology Venture Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/general-technology-venture-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 33% |
| Pharmaceutical | 3 | 33% |
| Industrial | 2 | 22% |
| Health Care | 2 | 22% |
| Manufacturing | 2 | 22% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 33% |
| Series D | 2 | 22% |
| Series A | 1 | 11% |
| Series C | 1 | 11% |
| Series E | 1 | 11% |

6 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jingming BAO | General Manager | 1 | https://shizune.co/investors/profile/jingming-bao |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SinoTau | SinoTau is a total solution provider specializing in generic drugs and innovative drugs. | $151.9M | Series E | Jul 03, 2023 |  |
| Eplus 3d | Eplus 3d is committed to the research and development and promotion of industrial-grade 3D printing (additive manufacturing) systems and application technologies. With MPBF™ metal 3D printing technology as the core, it provides aerospace, high-performance industrial manufacturing, mold manufacturing, and precision Provides professional additivemanufacturing application solutions in medical and other fields. |  | Series B | May 25, 2023 |  |
| Suzhou Kerun New Materials | Suzhou Kerun New Materials is an enterprise focusing on the R&D and production of perfluorinated ion membranes for fuel cell proton exchange membranes, vanadium batteries, and hydrogen production by electrolysis in the field of clean energy. The company was founded by Mr. Yang Dawei. | $35.6M | Series C | Jan 30, 2023 |  |
| Deep Vision | Deep Vision is a supplier of high-precision intelligent visual inspection solutions in the industrial field. Deep Vision has independent research and development capabilities of intelligent AI cameras & 3D cameras, optical design capabilities, research and development capabilities of multiple algorithm libraries, research and developmentcapabilities of FPGA platform image acquisition and processing systems, and design and manufacturing capabilities of automation equipment. | $15.7M | Series A | Mar 21, 2022 |  |
| MeetFuture China | MeetFuture China is a technology-driven company that supplies automated transmission systems for the pan-semiconductor industry.It provides automation solutions for leading companies in the semiconductor field since 2016 and provided a highly advantageous overall for industrial upgrading and development with independent and controllable coretechnologies. | $4.4M | Series B | Mar 14, 2022 |  |
| Yikon Genomics | Yikon Genomics is a leading solution-based single cell sequencing company. Currently based on the patented MALBAC® technology from Harvard University, Yikon provides complete solutions in the fields of reproductive health and cancer diagnostics with liquid tumor biopsy. The MALBAC-PGS™ and MALBAC-PGD™ solutions offer the most accurate andcomprehensive embryo testing results for physicians to choose the best embryos with balanced chromosomal copy numbers,without inheriting the known disease-associated alleles. The MALBAC-PGS™ and MALBAC-PGD™ solutions have helped thousands of couples to achieve successful pregnancies. Yikon will continue to interpret the code of life and bring people the hope and joy of life. | $38.7M | Series D | May 06, 2021 |  |
| Percutek Therapeutics | Percutek Therapeutics is a cardiovascular interventional device research and development manufacturer, mainly engaged in the research and development and production of cardiac and vascular related Class III minimally invasive interventional medical devices, dedicated to providing patients with safe interventional devices for cardiovascular clinicalMedical solutions, etc. | $14.2M | Series D | Jun 24, 2019 |  |
| 7LeKang (7lk) | Founded in 2011, 7LeKang operates nine offline stores and an online pharmacy platform |  | Corporate Round | Apr 17, 2019 |  |
| Cygnus Biosciences | Cygnus Biosciences (Beijing) Co., Ltd. is a high-tech company specializing in R & D and industrialization of gene sequencing platform and committed to clinical medicine screening and diagnosis. | $19.6M | Series B | Nov 14, 2017 |  |

9 of 9 investments shown.

## Co-investors
- [ZGC Group](https://shizune.co/investors/profile/zgc-group) — VC Fund, 2 deals together
- [ZGC Group](https://shizune.co/investors/profile/zhongguancun-qihang-vc) — VC Fund, 2 deals together
- [Air Development Fund](https://shizune.co/investors/profile/air-development-fund) — VC Fund, 1 deal together
- [BAIC Capital](https://shizune.co/investors/profile/baic-capital) — VC Fund, 1 deal together
- [Jinggong Hongyuan](https://shizune.co/investors/profile/beijing-jinggong-hongyuan-venture-capital-center) — VC Fund, 1 deal together
- [Bojiang Capital](https://shizune.co/investors/profile/bojiang-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does General Technology Venture Capital invest in?

General Technology Venture Capital invests primarily in Biotechnology, Pharmaceutical and Industrial startups, most often at Series B and Series D stage. Most of the 9 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact General Technology Venture Capital?

Public channels for General Technology Venture Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at General Technology Venture Capital?

The team at General Technology Venture Capital includes Jingming BAO (General Manager). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co